Drugs / Human BCMA Targeted T Cells Injection
Human BCMA Targeted T Cells Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05594797 | Jul 2022 → Jul 2025 overdue | plasma cell myeloma | Hrain Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human BCMA Targeted T Cells Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05594797 ↗ |
| Modality | Cell therapy | “BCMA CAR+ T cells” NCT05594797 ↗ |